The Group's principal activity is to develop and distribute pharmaceutical products. The Group develops innovative drugs used in therapeutic areas in oncology, endocrinology and neuromuscular disorders. Some of their products include Decapeptyl, Somatuline, NutropinAq, Autogel, Forlax, Tanakan, Testim and Dysport. The Group also offers products on primary care which includes the areas of gastroenterology, cardiovascular and cognitive disorders. The Group operates throughout the world, In 2008, the Group acquired Vernalis Pharmaceuticals and Tercica Inc.
Alacra Alerts:
Receive alerts on the latest reports on Ipsen
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
